Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Rahika 150mg Tablet
Manufacturer/Marketed By : NOVARTIS INDIA LTD
$164.57 $156.34
Sidmex Inovia offers bulk export supply of Rahika 150mg Tablet (CAPMATINIB) for hospitals, distributors and tender buyers. Request a quote with your quantity and destination country.Documents, cold-chain shipping and tenders:...
CAPMATINIB
Active Pharmaceutical Ingredient
Rahika 150mg Tablet
$164.57
$156.34
Sidmex Inovia offers bulk export supply of Rahika 150mg Tablet (CAPMATINIB) for hospitals, distributors and tender buyers. Request a quote with your quantity and destination country.
Documents, cold-chain shipping and tenders: see our Export FAQ.
Priority markets: United Arab Emirates, Brazil, Turkey, Singapore, Kenya, Somalia, Ghana, Saudi Arabia, Mauritius, Nigeria, Tanzania, Senegal, Democratic Republic of the Congo, Mali. We also export worldwide, including:
Middle East: Oman, Qatar, Kuwait, Bahrain, Iraq, Jordan, Lebanon, Yemen, Iran
Africa: Egypt, Algeria, Morocco, Libya, Burkina Faso, Côte d'Ivoire, Gambia, Rwanda, Ethiopia, Djibouti, South Africa, Zimbabwe
Asia: Sri Lanka, Bangladesh, Nepal, Maldives, Philippines, Vietnam, Laos, Malaysia, Thailand, Taiwan
CIS & Eastern Europe: Russia, Kazakhstan, Uzbekistan, Azerbaijan, Georgia, Serbia, Latvia, Tajikistan
Latin America & Caribbean: Mexico, Chile, Peru, Colombia, Bolivia, Venezuela
Europe & Other: Switzerland, United Kingdom, Canada
Related products we supply: Alburel 20 gm/100 ml Injection
Rahika 150mg tablet contains the active ingredient Capmatinib. It is an anti-cancer medicine that belongs to the class of medications called protein kinase inhibitors. It is used to treat adults with a type of lung cancer called non-small cell lung cancer (NSCLC) that has spread to other body parts or is caused by a change (mutation) in a gene that makes an enzyme called MET in adults. Do not take this medicine if you are allergic to Rahika 150mg tablet or any ingredients. Inform the physician if you have or have ever had lung or breathing problems other than your lung cancer, liver problems, or pancreatic problems. Inform your physician if you have any symptoms of an allergic reaction, including rash, hives, fever, difficulty breathing, or low blood pressure. This medicine is not recommended for children and adolescents below 18 years of age. Avoid getting pregnant and breastfeeding during the treatment. Use effective contraception to avoid pregnancy. The common side effects of Rahika 150mg tablet are swelling in the face, and body, nausea, tiredness, vomiting, shortness of breath, and decreased appetite.
Active Pharmaceutical Ingredient
Uses
• Non-small cell lung cancer (NSCLC)
Benefits
Rahika 150mg tablet is a kinase inhibitor that targets mesenchymal-epithelial transition (MET). It works by blocking the action of this abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells.
Side Effects
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them.
Most Common Side Effects
• Vomiting
• Liver injury
• Muscle pain
• Shortness of breath
• Lung infection
• Respiratory disease
Common Side Effects
• Swelling in the face, and body
• Decrease in appetite
• Nausea
• Cough
• Fatigue
How To Use
It is an orally available prescription drug. Your doctor will decide the dose and duration of Rahika 150mg tablet based on the disease condition and other factors. Always take this medicine as prescribed by your doctor. Take the tablet with or without food. Do not break, chew, crush, or break the tablet. Swallow the whole tablet with water.
Safety Advice
• Breast Feeding: Breastfeeding is not recommended in patients taking Rahika 150mg tablet because the medicine passes into the breast milk in small amounts and may harm your baby. Do not breastfeed during the treatment.
• Alcohol: It is unknown whether it is safe to consume alcohol with Rahika 150mg tablet. Please consult your doctor.
• Liver: Rahika 150mg tablet should be used cautiously in patients with liver problems. Dose adjustments are necessary for liver failure patients. Inform your physician if you have any liver diseases before initiating the therapy.
• Lungs: Rahika 150mg tablet should be cautiously administered in patients with lung problems other than lung cancer. Inform your physician if you have any lung diseases before initiating the therapy.
• Driving: It is unknown whether Rahika 150mg tablet alters the ability to drive or operate heavy machinery. If you feel dizzy or sleepy, avoid driving and consult your doctor.
• Pregnancy: Do not take Rahika 150mg tablet if you are pregnant because this may harm the unborn baby. Inform your physician if you are pregnant, suspecting, or planning to get pregnant during the treatment. Use effective contraception during the treatment and for 7 days after your last dose.
Disclaimer
Sidmex Inovia strives to provide accurate and reliable information; however, all content on this website, including product descriptions and compositions, is for informational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment.
Users are advised to consult a qualified healthcare professional before making any medical decisions. The information provided should not be used for self-diagnosis or self-medication.
All products listed are intended strictly for B2B and bulk inquiry purposes only. Sidmex Inovia does not promote direct consumer use and aims to support, not replace, the healthcare professional–patient relationship.
Product names, trademarks, and brands belong to their respective owners, and their use does not imply any affiliation or endorsement. Sidmex Inovia shall not be held responsible for any consequences arising from the use of the information provided on this website.